Cargando…
Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease
Autores principales: | Danho, Rabi, Schildkraut, Jodie A., Zweijpfenning, Sanne M.H., Svensson, Elin M., Pennings, Lian J., Kuipers, Saskia, Wertheim, Heiman F.L., Boeree, Martin J., Hoefsloot, Wouter, van Ingen, Jakko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Chest Physicians
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941609/ https://www.ncbi.nlm.nih.gov/pubmed/34391756 http://dx.doi.org/10.1016/j.chest.2021.08.046 |
Ejemplares similares
-
The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease
por: Schildkraut, Jodie A., et al.
Publicado: (2023) -
Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study
por: Zweijpfenning, Sanne M.H., et al.
Publicado: (2021) -
Subtle immunodeficiencies in nodular–bronchiectatic Mycobacterium avium complex lung disease
por: Bruno, Mariolina, et al.
Publicado: (2020) -
Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study
por: Henriette Zweijpfenning, Sanne Maria, et al.
Publicado: (2022) -
The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands
por: Schildkraut, Jodie Anne, et al.
Publicado: (2021)